In a patient with M0CRPC with PSA doubling time < 6 months, will you wait
until the absolute PSA value is >2, or is PSADT alone sufficient to start an AR targeted agent?
In the SPARTAN trial, median PSA at study entry was ~ 7. Does the MFS benefit extend to patients with low PSA(< 2 or < 1)?